Keyword: Medicare

Federal officials unveiled changes to Medicare Part B this week that could result in lower sales for Amgen and Regeneron.

PhRMA called new donut-hole drug discounts a "massive bailout" for payers, but the insurance lobby says pharma's arguments are "ridiculous."

Pharma suffered a blow in the Senate's budget deal, but how much will drugmakers really lose? Not a lot, on average, but some will take a bigger hit.

Pharma stands to prevail again in Washington, D.C., if a new Part D rule proposal from the Centers for Medicare & Medicaid Services makes its way into law.

A new study in JAMA has put the focus back on the price of Mallinckrodt's controversial med, H.P. Acthar gel.

Gilead hit with revived lawsuit claiming it sourced a key HIV drug ingredient from an unapproved Chinese manufacturer.

One prominent pharma CEO figures overhauling healthcare won't take a few weeks of work. Think years—even decades.

If a proposed change in the way Medicare pays for injected drugs that doctors give at their offices goes forward, some companies will be hit harder than others. And according to a new report, one drugmaker in particular is at risk: Regeneron. And that is because of its strength in the marketplace, Eylea.

Amid a Republican push to repeal and replace Obamacare, Pfizer CEO Ian Read took his drug pricing message to the Washington press corps.

President Donald Trump, not content with making drugs more affordable in the U.S., says he's aiming to push prices lower than anywhere else in the world.